Cytokine and lipid mediator networks in tuberculosis

A major approach for immunologic intervention in tuberculosis involves redirecting the outcome of the host immune response from the induction of disease to pathogen control. Cytokines and lipid mediators known as eicosanoids play key roles in regulating this balance and as such represent important targets for immunologic intervention. While the evidence for cytokine/eicosanoid function derives largely from the investigation of murine and zebrafish experimental infection models, clinical studies have confirmed the existence of many of the same pathways in tuberculosis patients. Here, we summarize new data that reveal important intersections between the cytokine and eicosanoid networks in the host response to mycobacteria and discuss how targeting this crosstalk can promote resistance to lethal Mycobacterium tuberculosis infection. This approach could lead to new host‐directed therapies to be used either as an adjunct for improving the efficacy of standard antibiotic treatment or for the management of drug‐resistant infections.

[1]  A. Sher,et al.  Type I interferons in infectious disease , 2015, Nature Reviews Immunology.

[2]  D. Barber,et al.  Defining features of protective CD4 T cell responses to Mycobacterium tuberculosis. , 2014, Current opinion in immunology.

[3]  A. Sher,et al.  Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon crosstalk , 2014, Nature.

[4]  Charles N. Serhan,et al.  Pro-resolving lipid mediators are leads for resolution physiology , 2014, Nature.

[5]  Vishva M. Dixit,et al.  Mechanisms and Functions of Inflammasomes , 2014, Cell.

[6]  P. A. Assis,et al.  Mycobacterium tuberculosis expressing phospholipase C subverts PGE2 synthesis and induces necrosis in alveolar macrophages , 2014, BMC Microbiology.

[7]  G. Wong,et al.  Targeted prostaglandin E2 inhibition enhances antiviral immunity through induction of type I interferon and apoptosis in macrophages. , 2014, Immunity.

[8]  D. Barber,et al.  Cutting Edge: Control of Mycobacterium tuberculosis Infection by a Subset of Lung Parenchyma–Homing CD4 T Cells , 2014, The Journal of Immunology.

[9]  S. Kaufmann,et al.  Progress in tuberculosis vaccine development and host-directed therapies--a state of the art review. , 2014, The Lancet. Respiratory medicine.

[10]  D. Gilroy,et al.  Proresolving lipid mediators and mechanisms in the resolution of acute inflammation. , 2014, Immunity.

[11]  S. Behar,et al.  Macrophages clean up: efferocytosis and microbial control. , 2014, Current opinion in microbiology.

[12]  D. Barber,et al.  Intravascular staining for discrimination of vascular and tissue leukocytes , 2014, Nature Protocols.

[13]  T. Hawn,et al.  Host-Directed Therapeutics for Tuberculosis: Can We Harness the Host? , 2013, Microbiology and Molecular Reviews.

[14]  F. Sutterwala,et al.  Cutting Edge: Mycobacterium tuberculosis but Not Nonvirulent Mycobacteria Inhibits IFN-β and AIM2 Inflammasome–Dependent IL-1β Production via Its ESX-1 Secretion System , 2013, The Journal of Immunology.

[15]  D. Chaussabel,et al.  TPL-2–ERK1/2 Signaling Promotes Host Resistance against Intracellular Bacterial Infection by Negative Regulation of Type I IFN Production , 2013, The Journal of Immunology.

[16]  L. Ramakrishnan,et al.  TB: the Yin and Yang of lipid mediators. , 2013, Current opinion in pharmacology.

[17]  C. Taher,et al.  Infection Rate and Tissue Localization of Murine IL-12p40-Producing Monocyte-Derived CD103+ Lung Dendritic Cells during Pulmonary Tuberculosis , 2013, PloS one.

[18]  Halli E. Miller,et al.  IL12B expression is sustained by a heterogenous population of myeloid lineages during tuberculosis. , 2013, Tuberculosis.

[19]  Ana C Anderson,et al.  IL-1β Promotes Antimicrobial Immunity in Macrophages by Regulating TNFR Signaling and Caspase-3 Activation , 2013, The Journal of Immunology.

[20]  Robert J Wilkinson,et al.  The immune response in tuberculosis. , 2013, Annual review of immunology.

[21]  L. Lenz,et al.  Differential effects of type I and II interferons on myeloid cells and resistance to intracellular bacterial infections , 2013, Immunologic research.

[22]  W. Bishai,et al.  An important role of prostanoid receptor EP2 in host resistance to Mycobacterium tuberculosis infection in mice. , 2012, The Journal of infectious diseases.

[23]  Hardy Kornfeld,et al.  Nitric oxide controls the immunopathology of tuberculosis by inhibiting NLRP3 inflammasome–dependent processing of IL-1β , 2012, Nature Immunology.

[24]  V. Deretic,et al.  Autophagy protects against active tuberculosis by suppressing bacterial burden and inflammation , 2012, Proceedings of the National Academy of Sciences.

[25]  C. Khor,et al.  Genome-Wide Expression Profiling Identifies Type 1 Interferon Response Pathways in Active Tuberculosis , 2012, PloS one.

[26]  S. Fortune,et al.  Efferocytosis is an innate antibacterial mechanism. , 2012, Cell host & microbe.

[27]  Steven B. Bradfute,et al.  TBK-1 promotes autophagy-mediated antimicrobial defense by controlling autophagosome maturation. , 2012, Immunity.

[28]  J. Ernst,et al.  Dynamic Roles of Type I and Type II IFNs in Early Infection with Mycobacterium tuberculosis , 2012, The Journal of Immunology.

[29]  D. Portnoy,et al.  Mycobacterium tuberculosis activates the DNA-dependent cytosolic surveillance pathway within macrophages. , 2012, Cell host & microbe.

[30]  L. Ramakrishnan Revisiting the role of the granuloma in tuberculosis , 2012, Nature Reviews Immunology.

[31]  John P. Ray,et al.  Host Genotype-Specific Therapies Can Optimize the Inflammatory Response to Mycobacterial Infections , 2012, Cell.

[32]  W. Bishai,et al.  Successful Shortening of Tuberculosis Treatment Using Adjuvant Host-Directed Therapy with FDA-Approved Phosphodiesterase Inhibitors in the Mouse Model , 2012, PloS one.

[33]  L. Miller,et al.  Host-pathogen interactions between the skin and Staphylococcus aureus. , 2012, Current opinion in microbiology.

[34]  J. Tschopp,et al.  Activation of the NLRP3 inflammasome by Mycobacterium tuberculosis is uncoupled from susceptibility to active tuberculosis , 2012, European journal of immunology.

[35]  A. Sher,et al.  Innate and adaptive interferons suppress IL-1α and IL-1β production by distinct pulmonary myeloid subsets during Mycobacterium tuberculosis infection. , 2011, Immunity.

[36]  B. Nandi,et al.  Regulation of neutrophils by interferon-γ limits lung inflammation during tuberculosis infection , 2011, The Journal of experimental medicine.

[37]  T. Myers,et al.  This information is current as Production in Human Macrophages β Type I IFN Signaling To Regulate IL-1 Triggers Host Mycobacterium tuberculosis , 2011 .

[38]  G. Kaplan,et al.  Phosphodiesterase-4 Inhibition Alters Gene Expression and Improves Isoniazid – Mediated Clearance of Mycobacterium tuberculosis in Rabbit Lungs , 2011, PLoS pathogens.

[39]  A. Sher,et al.  Role of innate cytokines in mycobacterial infection , 2011, Mucosal Immunology.

[40]  M. Glickman,et al.  A Gamma Interferon Independent Mechanism of CD4 T Cell Mediated Control of M. tuberculosis Infection in vivo , 2011, PLoS pathogens.

[41]  J. Flynn,et al.  Macrophages and control of granulomatous inflammation in tuberculosis , 2011, Mucosal Immunology.

[42]  C. Sassetti,et al.  Mycobacterium tuberculosis Induces an Atypical Cell Death Mode to Escape from Infected Macrophages , 2011, PloS one.

[43]  L. Joosten,et al.  Inflammasome activation and IL-1β and IL-18 processing during infection. , 2011, Trends in immunology.

[44]  A. Sher,et al.  CD4 T Cells Promote Rather than Control Tuberculosis in the Absence of PD-1–Mediated Inhibition , 2011, The Journal of Immunology.

[45]  V. Kuchroo,et al.  Tim3 binding to galectin-9 stimulates antimicrobial immunity , 2010, The Journal of experimental medicine.

[46]  G. Kaplan,et al.  Specific T cell frequency and cytokine expression profile do not correlate with protection against tuberculosis after bacillus Calmette-Guérin vaccination of newborns. , 2010, American journal of respiratory and critical care medicine.

[47]  S. Behar,et al.  Evasion of innate immunity by Mycobacterium tuberculosis: is death an exit strategy? , 2010, Nature Reviews Microbiology.

[48]  J. Tschopp,et al.  NALP3 is not necessary for early protection against experimental tuberculosis. , 2010, Immunobiology.

[49]  M. Braunstein,et al.  Granuloma Formation and Host Defense in Chronic Mycobacterium tuberculosis Infection Requires PYCARD/ASC but Not NLRP3 or Caspase-1 , 2010, PloS one.

[50]  J. Pedrosa,et al.  Pathological role of interleukin 17 in mice subjected to repeated BCG vaccination after infection with Mycobacterium tuberculosis , 2010, The Journal of experimental medicine.

[51]  S. Behar,et al.  Eicosanoid pathways regulate adaptive immunity to Mycobacterium tuberculosis , 2010, Nature Immunology.

[52]  J. Keane,et al.  How tumour necrosis factor blockers interfere with tuberculosis immunity , 2010, Clinical and experimental immunology.

[53]  Virginia Pascual,et al.  An Interferon-Inducible Neutrophil-Driven Blood Transcriptional Signature in Human Tuberculosis , 2010, Nature.

[54]  G. Bancroft,et al.  Enhanced protection to Mycobacterium tuberculosis infection in IL-10-deficient mice is accompanied by early and enhanced Th1 responses in the lung , 2010, European journal of immunology.

[55]  A. Sher,et al.  Intranasal Poly-IC treatment exacerbates tuberculosis in mice through the pulmonary recruitment of a pathogen-permissive monocyte/macrophage population. , 2010, The Journal of clinical investigation.

[56]  D. Underhill,et al.  Faculty Opinions recommendation of Caspase-1 independent IL-1beta production is critical for host resistance to mycobacterium tuberculosis and does not require TLR signaling in vivo. , 2010 .

[57]  A. Sher,et al.  Cutting Edge: Caspase-1 Independent IL-1β Production Is Critical for Host Resistance to Mycobacterium tuberculosis and Does Not Require TLR Signaling In Vivo , 2010, The Journal of Immunology.

[58]  David M. Tobin,et al.  The lta4h Locus Modulates Susceptibility to Mycobacterial Infection in Zebrafish and Humans , 2010, Cell.

[59]  L. Lenz,et al.  The Journal of Experimental Medicine CORRESPONDENCE , 2005 .

[60]  S. Taki Faculty Opinions recommendation of Induction of IFN-alphabeta enables Listeria monocytogenes to suppress macrophage activation by IFN-gamma. , 2010 .

[61]  A. Myers,et al.  Tumor necrosis factor neutralization results in disseminated disease in acute and latent Mycobacterium tuberculosis infection with normal granuloma structure in a cynomolgus macaque model. , 2010, Arthritis and rheumatism.

[62]  J. Flynn,et al.  The spectrum of latent tuberculosis: rethinking the biology and intervention strategies , 2009, Nature Reviews Microbiology.

[63]  E. Bateman,et al.  Immunomodulation with Recombinant Interferon-γ1b in Pulmonary Tuberculosis , 2009, PloS one.

[64]  S. Fortune,et al.  NOD2, RIP2 and IRF5 Play a Critical Role in the Type I Interferon Response to Mycobacterium tuberculosis , 2009, PLoS pathogens.

[65]  S. Fortune,et al.  Mycobacterium tuberculosis evades macrophage defenses by inhibiting plasma membrane repair , 2009, Nature Immunology.

[66]  C. Dinarello,et al.  Immunological and inflammatory functions of the interleukin-1 family. , 2009, Annual review of immunology.

[67]  A. Cooper,et al.  Cell-mediated immune responses in tuberculosis. , 2009, Annual review of immunology.

[68]  Hardy Kornfeld,et al.  Macrophage Apoptosis in Tuberculosis , 2009, Yonsei medical journal.

[69]  L. Ramakrishnan,et al.  The Role of the Granuloma in Expansion and Dissemination of Early Tuberculous Infection , 2009, Cell.

[70]  S. Khader,et al.  The role of cytokines in the initiation, expansion, and control of cellular immunity to tuberculosis , 2008, Immunological reviews.

[71]  Minjian Chen,et al.  Lipid mediators in innate immunity against tuberculosis: opposing roles of PGE2 and LXA4 in the induction of macrophage death , 2008, The Journal of experimental medicine.

[72]  W. Jacobs,et al.  Tuberculosis: unsealing the apoptotic envelope , 2008, Nature Immunology.

[73]  E. Brown,et al.  ESX‐1‐dependent cytolysis in lysosome secretion and inflammasome activation during mycobacterial infection , 2008, Cellular microbiology.

[74]  Hannah E. Volkman,et al.  Tumor necrosis factor signaling mediates resistance to mycobacteria by inhibiting bacterial growth and macrophage death. , 2008, Immunity.

[75]  Charles N. Serhan,et al.  Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators , 2008, Nature Reviews Immunology.

[76]  L. González-Méndez,et al.  Adjuvant interferon gamma in patients with pulmonary atypical Mycobacteriosis: A randomized, double-blind, placebo-controlled study , 2008, BMC infectious diseases.

[77]  B. Ryffel,et al.  IL-1 Receptor-Mediated Signal Is an Essential Component of MyD88-Dependent Innate Response to Mycobacterium tuberculosis Infection , 2007, The Journal of Immunology.

[78]  I. Orme,et al.  The Hypervirulent Mycobacterium tuberculosis Strain HN878 Induces a Potent TH1 Response followed by Rapid Down-Regulation1 , 2007, The Journal of Immunology.

[79]  J. Flynn,et al.  Tumor necrosis factor and tuberculosis. , 2007, The journal of investigative dermatology. Symposium proceedings.

[80]  J. Johndrow,et al.  The Type I IFN Response to Infection with Mycobacterium tuberculosis Requires ESX-1-Mediated Secretion and Contributes to Pathogenesis1 , 2007, The Journal of Immunology.

[81]  S. Swain,et al.  Interleukin 12p40 is required for dendritic cell migration and T cell priming after Mycobacterium tuberculosis infection , 2006, The Journal of experimental medicine.

[82]  J. Flynn,et al.  Lessons from experimental Mycobacterium tuberculosis infections. , 2006, Microbes and infection.

[83]  Minjian Chen,et al.  A Mechanism of Virulence: Virulent Mycobacterium tuberculosis Strain H37Rv, but Not Attenuated H37Ra, Causes Significant Mitochondrial Inner Membrane Disruption in Macrophages Leading to Necrosis1 , 2006, The Journal of Immunology.

[84]  I. Orme,et al.  Virulent clinical isolates of Mycobacterium tuberculosis grow rapidly and induce cellular necrosis but minimal apoptosis in murine macrophages , 2006, Journal of leukocyte biology.

[85]  G. Kaplan,et al.  Hypervirulent M. tuberculosis W/Beijing strains upregulate type I IFNs and increase expression of negative regulators of the Jak-Stat pathway. , 2005, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[86]  G. Nau Faculty Opinions recommendation of IL-23 compensates for the absence of IL-12p70 and is essential for the IL-17 response during tuberculosis but is dispensable for protection and antigen-specific IFN-gamma responses if IL-12p70 is available. , 2005 .

[87]  S. Khader,et al.  IL-23 Compensates for the Absence of IL-12p70 and Is Essential for the IL-17 Response during Tuberculosis but Is Dispensable for Protection and Antigen-Specific IFN-γ Responses if IL-12p70 Is Available1 , 2005, The Journal of Immunology.

[88]  A. Sher,et al.  Host control of Mycobacterium tuberculosis is regulated by 5-lipoxygenase-dependent lipoxin production. , 2005, The Journal of clinical investigation.

[89]  P. Haslett,et al.  Adjunctive Thalidomide Therapy for Childhood Tuberculous Meningitis: Results of a Randomized Study , 2004, Journal of child neurology.

[90]  John L. Johnson,et al.  A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis , 2004, AIDS.

[91]  I. Orme,et al.  In Vivo IL-10 Production Reactivates Chronic Pulmonary Tuberculosis in C57BL/6 Mice1 , 2002, The Journal of Immunology.

[92]  C. Demangel,et al.  Autocrine IL‐10 impairs dendritic cell (DC)‐derived immune responses to mycobacterial infection by suppressing DC trafficking to draining lymph nodes and local IL‐12 production , 2002, European journal of immunology.

[93]  S. Mizuno,et al.  Role of Interleukin (IL)‐1 Type 1 Receptor in Mycobacterial Infection , 2001, Microbiology and immunology.

[94]  Joseph Keane,et al.  Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent , 2001 .

[95]  J. Casanova,et al.  Interleukin-12 receptor beta1 deficiency in a patient with abdominal tuberculosis. , 2001, The Journal of infectious diseases.

[96]  D. Rennick,et al.  Endogenous Inhibition of Antimycobacterial Immunity by IL‐10 Varies between Mycobacterial Species , 2001, Scandinavian journal of immunology.

[97]  G. Kaplan,et al.  Virulence of a Mycobacterium tuberculosis clinical isolate in mice is determined by failure to induce Th1 type immunity and is associated with induction of IFN-α/β , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[98]  T. van der Poll,et al.  Interleukin-1 signaling is essential for host defense during murine pulmonary tuberculosis. , 2000, The Journal of infectious diseases.

[99]  Y. Iwakura,et al.  Protective Role of Interleukin-1 in Mycobacterial Infection in IL-1 α/β Double-Knockout Mice , 2000, Laboratory Investigation.

[100]  Hardy Kornfeld,et al.  Virulent Mycobacterium tuberculosis Strains Evade Apoptosis of Infected Alveolar Macrophages1 , 2000, The Journal of Immunology.

[101]  J. Keane,et al.  Macrophage apoptosis in mycobacterial infections , 1999, Journal of leukocyte biology.

[102]  A. Sher,et al.  IL-12 promotes drug-induced clearance of Mycobacterium avium infection in mice. , 1998, Journal of immunology.

[103]  G. V. van Seventer,et al.  Type I IFNs inhibit human dendritic cell IL-12 production and Th1 cell development. , 1998, Journal of immunology.

[104]  I. Orme,et al.  Interleukin 12 (IL-12) Is Crucial to the Development of Protective Immunity in Mice Intravenously Infected with Mycobacterium tuberculosis , 1997, The Journal of experimental medicine.

[105]  W. Rom,et al.  Treatment of multidrug-resistant pulmonary tuberculosis with interferon-γ via aerosol , 1997, The Lancet.

[106]  A. Sher,et al.  In the absence of endogenous IL-10, mice acutely infected with Toxoplasma gondii succumb to a lethal immune response dependent on CD4+ T cells and accompanied by overproduction of IL-12, IFN-gamma and TNF-alpha. , 1996, Journal of immunology.

[107]  C. Lowenstein,et al.  Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. , 1995, Immunity.

[108]  I. Orme,et al.  Disseminated tuberculosis in interferon gamma gene-disrupted mice , 1993, The Journal of experimental medicine.

[109]  J. Flynn,et al.  An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection , 1993, The Journal of experimental medicine.

[110]  M. Meltzer,et al.  Cytokine‐Induced Synthesis of Nitrogen Oxides in Macrophages: A Protective Host Response to Leishmania and Other Intracellular Pathogens , 1991, Journal of leukocyte biology.

[111]  T. Clark,et al.  Distinct phases of blood gene expression pattern through tuberculosis treatment reflect modulation of the humoral immune response. , 2013, The Journal of infectious diseases.

[112]  D Repsilber,et al.  Human gene expression profiles of susceptibility and resistance in tuberculosis , 2011, Genes and Immunity.

[113]  B. Nandi,et al.  Regulation of Neutrophils by Interferon-\(\gamma\) Limits Lung Inflammation During Tuberculosis Infection , 2011 .

[114]  M. Neuenhahn,et al.  NF-kappaB is a negative regulator of IL-1beta secretion as revealed by genetic and pharmacological inhibition of IKKbeta. , 2007, Cell.

[115]  J. Casanova,et al.  Genetic dissection of immunity to mycobacteria: the human model. , 2002, Annual review of immunology.

[116]  Y. Iwakura,et al.  Protective role of interleukin-1 in mycobacterial infection in IL-1 alpha/beta double-knockout mice. , 2000, Laboratory investigation; a journal of technical methods and pathology.

[117]  W. Rom,et al.  Treatment of multidrug-resistant pulmonary tuberculosis with interferon-gamma via aerosol. , 1997, Lancet.